Anatumomab mafenatox (ABR-214936) is a 73 kDa recombinant protein engineered to target the tumor-associated antigen 5T4, commonly expressed in various malignancies. This biologic agent is a fusion of a modified form of staphylococcal enterotoxin A (SEA) and a murine Fab fragment, designed for precise recognition and binding to the 5T4 antigen. Commonly reported adverse effects associated with Anatumomab mafenatox include fever, hypotension, pain, nausea, and drowsiness, which should be considered in therapeutic settings. This product is pivotal for research focused on the characterization and treatment of cancers expressing the 5T4 antigen.
Anatumomab mafenatox (ABR-214936) is a 73 kDa recombinant protein engineered to target the tumor-associated antigen 5T4, commonly expressed in various malignancies. This biologic agent is a fusion of a modified form of staphylococcal enterotoxin A (SEA) and a murine Fab fragment, designed for precise recognition and binding to the 5T4 antigen. Commonly reported adverse effects associated with Anatumomab mafenatox include fever, hypotension, pain, nausea, and drowsiness, which should be considered in therapeutic settings. This product is pivotal for research focused on the characterization and treatment of cancers expressing the 5T4 antigen.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
